News & Events about Cytek Biosciences Inc.
Cytek Biosciences, Inc. (NASDAQ:CTKB Get Rating) CEO Wenbin Jiang sold 20,000 shares of the stock in a transaction dated Monday, April 10th. The stock was sold at an average price of $8.88, for a total transaction of $177,600.00. Following the transaction, the chief executive officer now owns 7,684,...
3 months ago
SALUGGIA, Italy,and FREMONT, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- DiaSorin (FTSE MIB: DIA) and Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced that Luminex Corporation, a wholly owned subsidiary of DiaSorin, has completed the sale of substantially all of its assets related to the Flow ...
3 months ago
New Agreement Enhances High-Parameter Panels on Cytek Cell Analysis SystemsFREMONT, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Delivering a boost to immuno-oncology and immunotherapy researchers, Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced that it has entered into a strategic partnership ...
6 months ago
New Digital Ecosystem Supports Full Spectrum Flow Cytometry Research from Panel Design to Data Acquisition
Cytek Cloud is the new digital ecosystem that supports full spectrum flow cytometry research from panel design to data acquisition.
FREMONT, Calif., Nov. 15, 2022 (GLOBE ...
7 months ago
Cytek Biosciences, Inc. (NASDAQ:CTKB Get Rating) CFO Patrik Jeanmonod sold 3,500 shares of the businesss stock in a transaction dated Monday, October 24th. The stock was sold at an average price of $15.16, for a total value of $53,060.00. Following the sale, the chief financial ...